Mainz Biomed N.V. cash flow to debt ratio of -426.97% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Mainz Biomed N.V.'s free cash flow has increased -30.64% from $-17.34M last year to $-12.03M, signaling increasing performance

Mainz Biomed N.V.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Mainz Biomed N.V.'s debt has decreased relative to shareholder equity from 0.54 last year to 0.03 today, signaling strengthened financials

Mainz Biomed N.V. has negative EBITDA, making leverage ratio unreliable

Mainz Biomed N.V.'s interest coverage ratio is -39.06, which means that the company struggles to meet interest obligations, signaling financial risk.

Mainz Biomed N.V.'s profit margin has decreased (21.31%) in the last year from -2.42K% to -2.94K%, signaling decreasing performance

Mainz Biomed N.V.'s short-term liabilities of $3.69M exceed its short-term assets of $1.84M, signaling financial risk

Mainz Biomed N.V.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Mainz Biomed N.V.'s return on equity of -325.93%, is lower than 15.00%, indicating bad performance

Mainz Biomed N.V.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Mainz Biomed N.V. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Mainz Biomed N.V. has negative free cash flow, indicating the company is burning cash rather than generating it

Mainz Biomed N.V. has negative free cash flow, indicating cash burn

Mainz Biomed N.V.'s yearly earnings has increased -25.13% since last year from $-21.65M to $-16.21M, signaling increasing performance

Mainz Biomed N.V.'s yearly revenue has decreased -39.92% since last year from $893.99K to $537.08K, signaling decreasing performance

ROIC -165.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Mainz Biomed N.V.'s 3-year revenue CAGR of 0.45% is positive, indicating growing revenue over the past 3 years

Mainz Biomed N.V. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance

Mainz Biomed N.V. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Mainz Biomed N.V. has insufficient data to evaluate this check.

Mainz Biomed N.V. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mainz Biomed N.V. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Mainz Biomed N.V. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Mainz Biomed N.V. has insufficient data to evaluate this check.

Mainz Biomed N.V. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Mainz Biomed N.V. has a price-to-book ratio of 3.24x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Mainz Biomed N.V. has a price-to-sales ratio of 51.85x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue